A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

Inclusion Criteria: * Histological or cytological evidence of melanoma, unresectable Stage III or Stage IV, any genotype, and any programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) status * Phase 1a: nivolumab + HCQ: any prior treatment, or treatment naïve * Phase 2: nivolumab + HCQ: * \- - Cohort 2a: prior immunotherapy in the adjuvant or metastatic setting is required * \- - Cohort 2b: anti-PD-1 Ab-naïve, but may have received any prior other therapy * Phase 1b nivolumab + ipilimumab + HCQ: anti-PD-1 refractory * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * At least one measurable site of disease by RECIST 1.1 criteria that has not been previously irradiated. * Fresh or archived primary or metastatic tissue available for submission for correlative analyses * Negative serum pregnancy test within 28 days prior to commencement of dosing in premenopausal women. Negative urine pregnancy test within 24 hours of starting treatment. * Able to swallow and retain oral medication and no clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels * Adequate baseline organ function Exclusion Criteria: * Known serious concurrent infection or medical illness, including psychiatric disorders, which would jeopardize the ability to receive the protocol treatment with reasonable safety. * Pregnant or breast-feeding. * Patients with brain metastases treated with …